Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 ...
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $70 from $45 and keeps an Overweight rating on the shares. The firm notes the FDA approved Arrowhead’s first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results